Multicentre Randomised Double-blind Superiority Trial With a Roll-over Phase to Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder
Latest Information Update: 11 Sep 2026
At a glance
- Drugs Escherichia-coli-strains (Primary)
- Indications Urinary tract infections
- Focus Therapeutic Use
- Acronyms RETRAIN
Most Recent Events
- 08 Sep 2026 Planned End Date changed from 1 Dec 2028 to 1 Dec 2029.
- 08 Sep 2026 Planned primary completion date changed from 1 Dec 2027 to 1 Dec 2029.
- 30 Dec 2024 Planned End Date changed from 1 Oct 2028 to 1 Dec 2028.